Lastet: description of the medicine and its use
Lastet (international name - Etoposide) is a cytostatic agent of plant origin produced by Nippon Kayaku Co. in Japan. The dosage form of Lastet is presented in capsules and solution for injection, with dosages from 25 mg to 100 mg.
Lastet is used to treat various types of cancer, such as small cell lung cancer, testicular cancer, chorionic carcinoma, Ewing's sarcoma, Kaposi's sarcoma, neuroblastoma, rhabdomyosarcoma, breast cancer, non-Hodgkin's lymphomas, lymphogranulomatosis and acute myeloid leukemia.
Although Lastet may be effective in the treatment of these types of cancer, its use may also cause side effects such as hematopoietic suppression, necrotizing enteropathy, toxic hepatitis, arterial hypotension with rapid intravenous administration, cardiac dysfunction, central nervous system lesions, reversible alopecia, phlebitis at the injection site and allergic reactions.
Contraindications to the use of Lastet are hypersensitivity, neutropenia, thrombocytopenia, impaired liver and kidney function, and pregnancy.
Concomitant use of Lastet with other cytostatics may increase the risk of developing myelosuppression.
There are no known cases of overdose with Lastet. However, when treating with this drug, it is recommended to ensure the availability of conditions for relieving complications of treatment, including a sterile box, a sufficient arsenal of antibiotics and the possibility of replacement therapy with blood components.
Treatment with Lastet should only be carried out by a physician experienced in chemotherapy and with the necessary conditions to manage complications of treatment.
Thus, Lastet is an effective cytostatic agent for the treatment of various types of cancer. However, its use can cause serious side effects, so you must strictly follow the instructions for use and treat only under the supervision of a physician.